WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock. The Company has granted the underwriter an option to purchase up to an additional 741,750 shares of common stock. The offering is expected to close on September 12, 2017, subject to customary closing conditions.
The Company intends to use the net proceeds of this offering for general corporate purposes, including working capital, research and development activities, capital expenditures and potential strategic transactions.
The underwriter intends to offer the shares from time to time for sale in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices.
BofA Merrill Lynch is acting as the sole underwriter of this offering.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.